Silence Therapeutics plc
Clinical-stage biotech developing siRNA medicines to silence disease-causing genes.
SLN | US
Overview
Corporate Details
- ISIN(s):
- US82686Q1013 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 12 HAMMERSMITH GROVE, LONDON
Description
Silence Therapeutics plc is a clinical-stage biotechnology company pioneering the design and development of medicines based on short-interfering RNA (siRNA). The company utilizes its proprietary technology platform to create precision-engineered therapies that selectively silence the expression of disease-causing genes. Its clinical pipeline focuses on addressing conditions with high unmet medical needs in therapeutic areas such as cardiovascular disease, hematology, and rare diseases. Key product candidates in development include zerlasiran, targeting cardiovascular risk, and divesiran for polycythemia vera. The company aims to provide transformative treatments for patients who have limited or inadequate therapeutic options.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-03-07 08:00 |
Notice of AGM
|
English | 13.6 KB | ||
| 2018-03-06 08:00 |
Preliminary results year ended 31 December 2017
|
English | 116.0 KB | ||
| 2018-03-05 08:00 |
Silence to present at Cowen Health Care Conference
|
English | 13.6 KB | ||
| 2018-02-22 16:40 |
Holding(s) in Company
|
English | 63.9 KB | ||
| 2018-02-20 08:00 |
Notice of Results
|
English | 13.1 KB | ||
| 2018-02-15 15:27 |
Additional Listing
|
English | 16.0 KB | ||
| 2018-02-02 12:38 |
Grant of share options and restricted stock units
|
English | 79.2 KB | ||
| 2018-02-02 09:58 |
Holding(s) in Company
|
English | 64.2 KB | ||
| 2018-01-31 12:48 |
Holding(s) in Company
|
English | 62.3 KB | ||
| 2018-01-22 08:00 |
Key European patent granted
|
English | 15.0 KB | ||
| 2017-07-14 09:00 |
CEO Ali Mortazavi appointed Chairman of Ultromics
|
English | 15.2 KB | ||
| 2017-07-10 09:41 |
IP update
|
English | 15.9 KB | ||
| 2017-07-03 16:34 |
Issue of claim in the UK High Courts
|
English | 14.9 KB | ||
| 2017-07-03 09:00 |
Change of Adviser
|
English | 13.4 KB | ||
| 2017-06-29 13:47 |
Holding(s) in Company
|
English | 52.3 KB |
Automate Your Workflow. Get a real-time feed of all Silence Therapeutics plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Silence Therapeutics plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Silence Therapeutics plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
